

References :

1. Gannavaram S, Bhattacharya P, Ismail N, Kaul A, Singh R, Nakhasi HL. Modulation of Innate Immune Mechanisms to Enhance Leishmania Vaccine-Induced Immunity: Role of Coinhibitory Molecules. *Front Immunol.* 2016 ;7:187.
2. Rezvan H, Moafi M. An overview on Leishmania vaccines: A narrative review article. *Vet Res Forum.* 2015 ;6:1-7.
3. Moafi M, Rezvan H, Sherkat R, Taleban R, Asilian A, Hamid Zarkesh-Esfahani S, Nilforoushzadeh MA, Jaffary F, Mansourian M, Sokhanvari F, Ansari N. Comparison of pro-inflammatory cytokines of non-healing and healing cutaneous leishmaniasis. *Scand J Immunol.* 2017 ;85:291-299.
4. McGwire BS, Satoskar AR. Leishmaniasis: clinical syndromes and treatment. *QJM.* 2014 ;107:7-14.
5. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M; WHO Leishmaniasis Control Team. Leishmaniasis worldwide and global estimates of its incidence. *PLoS One.* 2012 ;7:e35671.
6. Mathers CD, Ezzati M, Lopez AD. Measuring the burden of neglected tropical diseases: the global burden of disease framework. *PLoS Negl Trop Dis.* 2007 ;1:e114.
7. Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. *Trends Parasitol.* 2006 ;22:552-7.
8. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. *Lancet.* 2005 ;366:1561-77.
9. Nateghi Rostami M, Saghafipour A, Vesali E. A newly emerged cutaneous leishmaniasis focus in central Iran. *Int J Infect Dis.* 2013 ;17:e1198-206.

10. Quinnell RJ, Courtenay O. Transmission, reservoir hosts and control of zoonotic visceral leishmaniasis. *Parasitology*. 2009 ;136:1915-34.
11. Bern C, Maguire JH, Alvar J. Complexities of assessing the disease burden attributable to leishmaniasis. *PLoS Negl Trop Dis*. 2008 ;2:e313.
12. Elnaiem DA, Hassan HK, Ward RD. Phlebotomine sandflies in a focus of visceral leishmaniasis in a border area of eastern Sudan. *Ann Trop Med Parasitol*. 1997 ;91:307-18.
13. Bucheton B, Kheir MM, El-Safi SH, Hammad A, Mergani A, Mary C, Abel L, Dessein A. The interplay between environmental and host factors during an outbreak of visceral leishmaniasis in eastern Sudan. *Microbes Infect*. 2002 ;4:1449-57.
14. Alvar J, Bashaye S, Argaw D, Cruz I, Aparicio P, Kassa A, Orfanos G, Parreño F, Babaniyi O, Gudeta N, Cañavate C, Bern C. Kala-azar outbreak in Libo Kemkem, Ethiopia: epidemiologic and parasitologic assessment. *Am J Trop Med Hyg*. 2007 ;77:275-82.
15. Seaman J, Mercer AJ, Sondorp E. The epidemic of visceral leishmaniasis in western Upper Nile, southern Sudan: course and impact from 1984 to 1994. *Int J Epidemiol*. 1996 ;25:862-71.
16. Elnaiem DA, Hassan MM, Maingon R, Nureldin GH, Mekawi AM, Miles M, Ward RD. The Egyptian mongoose, *Herpestes ichneumon*, is a possible reservoir host of visceral leishmaniasis in eastern Sudan. *Parasitology*. 2001 ;122:531-6.
17. Dereure J, El-Safi SH, Bucheton B, Boni M, Kheir MM, Davoust B, Pratlong F, Feugier E, Lambert M, Dessein A, Dedet JP. Visceral leishmaniasis in eastern Sudan: parasite identification in humans and dogs; host-parasite relationships. *Microbes Infect*. 2003 ;5:1103-8.
18. Ready PD. Leishmaniasis emergence in Europe. *Euro Surveill*. 2010 ;15:19505.

19. Chitimia L, Muñoz-García CI, Sánchez-Velasco D, Lizana V, Del Río L, Murcia L, Fisa R, Riera C, Giménez-Font P, Jiménez-Montalbán P, Martínez-Ramírez A, Meseguer-Meseguer JM, García-Bacete I, Sánchez-Isarria MA, Sanchis-Monsonís G, García-Martínez JD, Vicente V, Segovia M, Berriatua E. Cryptic Leishmaniasis by *Leishmania infantum*, a feature of canines only? A study of natural infection in wild rabbits, humans and dogs in southeastern Spain. *Vet Parasitol.* 2011 ;181:12-6.
20. Jarvis JN, Lockwood DN. Clinical aspects of visceral leishmaniasis in HIV infection. *Curr Opin Infect Dis.* 2013 ;26:1-9.
21. Alvar J, Aparicio P, Aseffa A, Den Boer M, Cañavate C, Dedet JP, Gradoni L, Ter Horst R, López-Vélez R, Moreno J. The relationship between leishmaniasis and AIDS: the second 10 years. *Clin Microbiol Rev.* 2008 ;21:334-59.
22. Killick-Kendrick R. The life-cycle of *Leishmania* in the sandfly with special reference to the form infective to the vertebrate host. *Ann Parasitol Hum Comp.* 1990 ;65:37-42.
23. Guevara P, Pinto-Santíni D, Rojas A, Crisante G, Añez N, Ramirez JL. Green fluorescent protein-tagged *Leishmania* in phlebotomine sand flies. *J Med Entomol.* 2001 ;38:39-43.
24. Sacks D, Kamhawi S. Molecular aspects of parasite-vector and vector-host interactions in leishmaniasis. *Annu Rev Microbiol.* 2001 ;55:453-83.
25. <https://www.who.int/news-room/fact-sheets>
26. van Kooten C, Banchereau J. CD40-CD40 ligand. *J Leukoc Biol.* 2000 ;67:2-17.
27. Banchereau J, Bazan F, Blanchard D, Brière F, Galizzi JP, van Kooten C, Liu YJ, Rousset F, Saeland S. The CD40 antigen and its ligand. *Annu Rev Immunol.* 1994 ;12:881-922.
28. Danese S, Sans M, Fiocchi C. The CD40/CD40L costimulatory pathway in inflammatory bowel disease. *Gut.* 2004 ;53:1035-43.

29. Kamanaka M, Yu P, Yasui T, Yoshida K, Kawabe T, Horii T, Kishimoto T, Kikutani H. Protective role of CD40 in *Leishmania major* infection at two distinct phases of cell-mediated immunity. *Immunity*. 1996 ;4:275-81.
30. Soong L, Xu JC, Grewal IS, Kima P, Sun J, Longley BJ Jr, Ruddle NH, McMahon-Pratt D, Flavell RA. Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to *Leishmania amazonensis* infection. *Immunity*. 1996 ;4:263-73.
31. Nathan CF, Murray HW, Wiebe ME, Rubin BY. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. *J Exp Med*. 1983 ;158:670-89.
32. Reed SG. In vivo administration of recombinant IFN-gamma induces macrophage activation, and prevents acute disease, immune suppression, and death in experimental *Trypanosoma cruzi* infections. *J Immunol*. 1988 ;140:4342-7.
33. Awasthi A, Mathur R, Khan A, Joshi BN, Jain N, Sawant S, Boppana R, Mitra D, Saha B. CD40 signaling is impaired in *L. major*-infected macrophages and is rescued by a p38MAPK activator establishing a host-protective memory T cell response. *J Exp Med*. 2003 ;197:1037-43.
34. Mathur RK, Awasthi A, Wadhone P, Ramanamurthy B, Saha B. Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses. *Nat Med*. 2004 ;10:540-4.
35. Saljoughian N, Taheri T, Rafati S. Live vaccination tactics: possible approaches for controlling visceral leishmaniasis. *Front Immunol*. 2014 ;5:134.
36. Khalil EA, El Hassan AM, Zijlstra EE, Mukhtar MM, Ghalib HW, Musa B, Ibrahim ME, Kamil AA, Elsheikh M, Babiker A, Modabber F. Autoclaved *Leishmania major* vaccine for

prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. *Lancet*. 2000 ;356:1565-9.

37. Bruhn KW, Birnbaum R, Haskell J, Vanchinathan V, Greger S, Narayan R, Chang PL, Tran TA, Hickerson SM, Beverley SM, Wilson ME, Craft N. Killed but metabolically active *Leishmania infantum* as a novel whole-cell vaccine for visceral leishmaniasis. *Clin Vaccine Immunol*. 2012 ;19:490-8.

38. Coler RN, Reed SG. Second-generation vaccines against leishmaniasis. *Trends Parasitol*. 2005 ;21:244-9.

39. da Silva VO, Borja-Cabrera GP, Correia Pontes NN, de Souza EP, Luz KG, Palatnik M, Palatnik de Sousa CB. A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN). *Vaccine*. 2000 ;19:1082-92.

40. Borja-Cabrera GP, Correia Pontes NN, da Silva VO, Paraguai de Souza E, Santos WR, Gomes EM, Luz KG, Palatnik M, Palatnik de Sousa CB. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN). *Vaccine*. 2002 ;20:3277-84.

41. Borja-Cabrera GP, Santos FN, Bauer FS, Parra LE, Menz I, Morgado AA, Soares IS, Batista LM, Palatnik-de-Sousa CB. Immunogenicity assay of the Leishmune vaccine against canine visceral leishmaniasis in Brazil. *Vaccine*. 2008 ;26:4991-7.

42. Tonui WK, Mejia JS, Hochberg L, Mbow ML, Ryan JR, Chan AS, Martin SK, Titus RG. Immunization with *Leishmania major* exogenous antigens protects susceptible BALB/c mice against challenge infection with *L. major*. *Infect Immun*. 2004 ;72:5654-61.

43. Afrin F, Rajesh R, Anam K, Gopinath M, Pal S, Ali N. Characterization of *Leishmania donovani* antigens encapsulated in liposomes that induce protective immunity in BALB/c mice. *Infect Immun.* 2002 ;70:6697-706.
44. Sharma SK, Dube A, Nadeem A, Khan S, Saleem I, Garg R, Mohammad O. Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis. *Vaccine.* 2006 ;24:1800-10.
45. Heravi Shargh V, Jaafari MR, Khamesipour A, Jalali SA, Firouzmand H, Abbasi A, Badiee A. Cationic liposomes containing soluble *Leishmania* antigens (SLA) plus CpG ODNs induce protection against murine model of leishmaniasis. *Parasitol Res.* 2012 ;111:105-14.
46. Jaafari MR, Badiee A, Khamesipour A, Samiei A, Soroush D, Kheiri MT, Barkhordari F, McMaster WR, Mahboudi F. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of *Leishmania* (rgp63) encapsulated in cationic liposome. *Vaccine.* 2007 ;25:6107-17.
47. Bhowmick S, Ravindran R, Ali N. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with *Leishmania donovani*. *Infect Immun.* 2008 ;76:1003-15.
48. Mazumder S, Maji M, Das A, Ali N. Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against *Leishmania donovani* in BALB/c mice. *PLoS One.* 2011 ;6:e14644.
49. Masina S, M Gicheru M, Demotz SO, Fasel NJ. Protection against cutaneous leishmaniasis in outbred vervet monkeys using a recombinant histone H1 antigen. *J Infect Dis.* 2003 ;188:1250-7.

50. Moreno J, Nieto J, Masina S, Cañavate C, Cruz I, Chicharro C, Carrillo E, Napp S, Reymond C, Kaye PM, Smith DF, Fasel N, Alvar J. Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis. *Vaccine*. 2007 ;25:5290-300.
51. Morris RV, Shoemaker CB, David JR, Lanzaro GC, Titus RG. Sandfly maxadilan exacerbates infection with *Leishmania major* and vaccinating against it protects against *L. major* infection. *J Immunol*. 2001 ;167:5226-30.
52. Skeiky YA, Coler RN, Brannon M, Stromberg E, Greeson K, Crane RT, Webb JR, Campos-Neto A, Reed SG. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. *Vaccine*. 2002 ;20:3292-303.
53. Gradoni L, FogliaManzillo V, Pagano A, Piantedosi D, De Luna R, Gramiccia M, Scalone A, Di Muccio T, Oliva G. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from *Leishmania infantum* infection and to prevent disease progression in infected animals. *Vaccine*. 2005 ;23:5245-51.
54. Coler RN, Goto Y, Bogatzki L, Raman V, Reed SG. Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells. *Infect Immun*. 2007 ;75:4648-54.
55. Miret J, Nascimento E, Sampaio W, França JC, Fujiwara RT, Vale A, Dias ES, Vieira E, da Costa RT, Mayrink W, Campos Neto A, Reed S. Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f + MPL-SE vaccine to treat canine visceral leishmaniasis. *Vaccine*. 2008 ;26:1585-94.

56. Chakravarty J, Kumar S, Trivedi S, Rai VK, Singh A, Ashman JA, Laughlin EM, Coler RN, Kahn SJ, Beckmann AM, Cowgill KD, Reed SG, Sundar S, Piazza FM. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. *Vaccine*. 2011 ;29:3531-7.
57. Chhajer R, Ali N. Genetically modified organisms and visceral leishmaniasis. *Front Immunol*. 2014 ;5:213.
58. Titus RG, Gueiros-Filho FJ, de Freitas LA, Beverley SM. Development of a safe live *Leishmania* vaccine line by gene replacement. *Proc Natl Acad Sci U S A*. 1995 ;92:10267-71.
59. Veras P, Brodskyn C, Balestieri F, Freitas Ld, Ramos A, Queiroz A, Barral A, Beverley S, Barral-Netto M. A dhfr-ts- *Leishmania* major knockout mutant cross-protects against *Leishmania amazonensis*. *Mem Inst Oswaldo Cruz*. 1999 ;94:491-6.
60. Selvapandiyar A, Dey R, Nylén S, Duncan R, Sacks D, Nakhasi HL. Intracellular replication-deficient *Leishmania donovani* induces long lasting protective immunity against visceral leishmaniasis. *J Immunol*. 2009 ;183:1813-20.
61. Silvestre R, Cordeiro-Da-Silva A, Santarém N, Vergnes B, Sereno D, Ouaisi A. SIR2-deficient *Leishmania infantum* induces a defined IFN-gamma/IL-10 pattern that correlates with protection. *J Immunol*. 2007 ;179:3161-70.
62. Carrión J, Folgueira C, Soto M, Fresno M, Requena JM. *Leishmania infantum* HSP70-II null mutant as candidate vaccine against leishmaniasis: a preliminary evaluation. *Parasit Vectors*. 2011 ;4:150.
63. Breton M, Tremblay MJ, Ouellette M, Papadopoulou B. Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. *Infect Immun*. 2005 ;73:6372-82.

64. Mizbani A, Taheri T, Zahedifard F, Taslimi Y, Azizi H, Azadmanesh K, Papadopoulou B, Rafati S. Recombinant *Leishmania tarentolae* expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis. *Vaccine*. 2009 ;28:53-62.
65. Tsagozis P, Karagouni E, Dotsika E. Dendritic cells pulsed with peptides of gp63 induce differential protection against experimental cutaneous leishmaniasis. *Int J Immunopathol Pharmacol*. 2004 ;17:343-52.
66. Ahuja SS, Reddick RL, Sato N, Montalbo E, KostECKI V, Zhao W, Dolan MJ, Melby PC, Ahuja SK. Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection. *J Immunol*. 1999 ;163:3890-7.
67. Ghosh M, Pal C, Ray M, Maitra S, Mandal L, Bandyopadhyay S. Dendritic cell-based immunotherapy combined with antimony-based chemotherapy cures established murine visceral leishmaniasis. *J Immunol*. 2003 ;170:5625-9.
68. Agallou M, Margaroni M, Karagouni E. Cellular vaccination with bone marrow-derived dendritic cells pulsed with a peptide of *Leishmania infantum* KMP-11 and CpG oligonucleotides induces protection in a murine model of visceral leishmaniasis. *Vaccine*. 2011 ;29:5053-64.
69. Basu R, Bhaumik S, Haldar AK, Naskar K, De T, Dana SK, Walden P, Roy S. Hybrid cell vaccination resolves *Leishmania donovani* infection by eliciting a strong CD8⁺ cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13. *Infect Immun*. 2007 ;75:5956-66.
70. Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. *Nature*. 1992 ;356:152-4.

71. Gurusathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization*. *Annu Rev Immunol.* 2000 ;18:927-74.
72. Handman E, Noormohammadi AH, Curtis JM, Baldwin T, Sjölander A. Therapy of murine cutaneous leishmaniasis by DNA vaccination. *Vaccine.* 2000 ;18:3011-7.
73. Marques-da-Silva EA, Coelho EA, Gomes DC, Vilela MC, Masioli CZ, Tavares CA, Fernandes AP, Afonso LC, Rezende SA. Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-gamma production but does not protect BALB/c mice against *Leishmania chagasi* intravenous challenge. *Parasitol Res.* 2005 ;98:67-74.
74. Gomes DC, Pinto EF, de Melo LD, Lima WP, Larraga V, Lopes UG, Rossi-Bergmann B. Intranasal delivery of naked DNA encoding the LACK antigen leads to protective immunity against visceral leishmaniasis in mice. *Vaccine.* 2007 ;25:2168-72.
75. da Silva-Couto L, Ribeiro-Romão RP, Saavedra AF, da Silva Costa Souza BL, Moreira OC, Gomes-Silva A, Rossi-Bergmann B, Da-Cruz AM, Pinto EF. Intranasal vaccination with leishmanial antigens protects golden hamsters (*Mesocricetus auratus*) against *Leishmania (Viannia) Braziliensis* infection. *PLoS Negl Trop Dis.* 2015 ;9:e3439.
76. Basu R, Bhaumik S, Basu JM, Naskar K, De T, Roy S. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of *Leishmania donovani* that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. *J Immunol.* 2005 ;174:7160-71.
77. Sharma A, Madhubala R. Ubiquitin conjugation of open reading frame F DNA vaccine leads to enhanced cell-mediated immune response and induces protection against both antimony-susceptible and -resistant strains of *Leishmania donovani*. *J Immunol.* 2009 ;183:7719-31.

78. Bhaumik S, Basu R, Sen S, Naskar K, Roy S. KMP-11 DNA immunization significantly protects against *L. donovani* infection but requires exogenous IL-12 as an adjuvant for comparable protection against *L. major*. *Vaccine*. 2009 ;27:1306-16.
79. Rodríguez-Cortés A, Ojeda A, López-Fuertes L, Timón M, Altet L, Solano-Gallego L, Sánchez-Robert E, Francino O, Alberola J. Vaccination with plasmid DNA encoding KMP11, TRYP, LACK and GP63 does not protect dogs against *Leishmania infantum* experimental challenge. *Vaccine*. 2007 ;25:7962-71.
80. Saldarriaga OA, Travi BL, Park W, Perez LE, Melby PC. Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs. *Vaccine*. 2006 ;24:1928-40.
81. Guha R, Gupta D, Rastogi R, Vikram R, Krishnamurthy G, Bimal S, Roy S, Mukhopadhyay A. Vaccination with leishmania hemoglobin receptor-encoding DNA protects against visceral leishmaniasis. *Sci Transl Med*. 2013 ;5:202ra121.
82. Das S, Freier A, Boussoffara T, Das S, Oswald D, Losch FO, Selka M, Sacerdoti-Sierra N, Schönian G, Wiesmüller KH, Seifert K, Schroff M, Juhls C, Jaffe CL, Roy S, Das P, Louzir H, Croft SL, Modabber F, Walden P. Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis. *Sci Transl Med*. 2014 ;6:234ra56.
83. Lu S. Heterologous prime-boost vaccination. *Curr Opin Immunol*. 2009 ;21:346-51.
84. Gonzalo RM, del Real G, Rodriguez JR, Rodriguez D, Heljasvaara R, Lucas P, Larraga V, Esteban M. A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the *Leishmania infantum* P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis. *Vaccine*. 2002 ;20:1226-31.

85. Ramiro MJ, Zárata JJ, Hanke T, Rodriguez D, Rodriguez JR, Esteban M, Lucientes J, Castillo JA, Larraga V. Protection in dogs against visceral leishmaniasis caused by *Leishmania infantum* is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. *Vaccine*. 2003 ;21:2474-84.
86. Dondji B, Pérez-Jimenez E, Goldsmith-Pestana K, Esteban M, McMahon-Pratt D. Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis. *Infect Immun*. 2005 ;73:5286-9.
87. Ramos I, Alonso A, Peris A, Marcen JM, Abengozar MA, Alcolea PJ, Castillo JA, Larraga V. Antibiotic resistance free plasmid DNA expressing LACK protein leads towards a protective Th1 response against *Leishmania infantum* infection. *Vaccine*. 2009 ;27:6695-703.
88. Rafati S, Zahedifard F, Nazgouee F. Prime-boost vaccination using cysteine proteinases type I and II of *Leishmania infantum* confers protective immunity in murine visceral leishmaniasis. *Vaccine*. 2006 ;24:2169-75.
89. Saljoughian N, Taheri T, Zahedifard F, Taslimi Y, Doustdari F, Bolhassani A, Doroud D, Azizi H, Heidari K, Vasei M, NamvarAsl N, Papadopoulou B, Rafati S. Development of novel prime-boost strategies based on a tri-gene fusion recombinant *L. tarentolae* vaccine against experimental murine visceral leishmaniasis. *PLoS Negl Trop Dis*. 2013 ;7:e2174.
90. Widmann C, Gibson S, Jarpe MB, Johnson GL. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. *Physiol Rev*. 1999 ;79:143-80.
91. Gaestel M. Specificity of signaling from MAPKs to MAPKAPKs: kinases' tango nuevo. *Front Biosci*. 2008 ;13:6050-9.
92. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. *Microbiol Mol Biol Rev*. 2004 ;68:320-44.

93. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. *Endocr Rev.* 2001 ;22:153-83.
94. Coulombe P, Meloche S. Atypical mitogen-activated protein kinases: structure, regulation and functions. *Biochem Biophys Acta.* 2007 ;1773:1376-87.
95. Lu HT, Yang DD, Wysk M, Gatti E, Mellman I, Davis RJ, Flavell RA. Defective IL-12 production in mitogen-activated protein (MAP) kinase kinase 3 (Mkk3)-deficient mice. *EMBO J.* 1999 ;18:1845-57.
96. Hsu SC, Wu CC, Han J, Lai MZ. Involvement of p38 mitogen-activated protein kinase in different stages of thymocyte development. *Blood.* 2003 ;101:970-6.
97. Rincón M, Enslen H, Raingeaud J, Recht M, Zapton T, Su MS, Penix LA, Davis RJ, Flavell RA. Interferon-gamma expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway. *EMBO J.* 1998 ;17:2817-29.
98. Yang J, Zhu H, Murphy TL, Ouyang W, Murphy KM. IL-18-stimulated GADD45 beta required in cytokine-induced, but not TCR-induced, IFN-gamma production. *Nat Immunol.* 2001 ;2:157-64.
99. Merritt C, Enslen H, Diehl N, Conze D, Davis RJ, Rincón M. Activation of p38 mitogen-activated protein kinase in vivo selectively induces apoptosis of CD8(+) but not CD4(+) T cells. *Mol Cell Biol.* 2000 ;20:936-46.
100. Dell KR, Engel JN. Stage-specific regulation of protein phosphorylation in *Leishmania major*. *Mol Biochem Parasitol.* 1994 ;64:283-92.

101. Parsons M, Worthey EA, Ward PN, Mottram JC. Comparative analysis of the kinomes of three pathogenic trypanosomatids: *Leishmania major*, *Trypanosoma brucei* and *Trypanosoma cruzi*. *BMC Genomics*. 2005 ;6:127.
102. Wiese M, Wang Q, Görcke I. Identification of mitogen-activated protein kinase homologues from *Leishmania mexicana*. *Int J Parasitol*. 2003 ;33:1577-87.
103. Ivens AC, Peacock CS, Worthey EA et al. The genome of the kinetoplastid parasite, *Leishmania major*. *Science*. 2005 ;309:436-42.
104. Miyata Y, Nishida E. Distantly related cousins of MAP kinase: biochemical properties and possible physiological functions. *Biochem Biophys Res Commun*. 1999 ;266:291-5.
105. Mazzucchelli R, Durum SK. Interleukin-7 receptor expression: intelligent design. *Nat Rev Immunol*. 2007 ;7:144-54.
106. Link A, Vogt TK, Favre S, Britschgi MR, Acha-Orbea H, Hinz B, Cyster JG, Luther SA. Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells. *Nat Immunol*. 2007 ;8:1255-65.
107. Guimond M, Veenstra RG, Grindler DJ, Zhang H, Cui Y, Murphy RD, Kim SY, Na R, Hennighausen L, Kurtulus S, Erman B, Matzinger P, Merchant MS, Mackall CL. Interleukin-7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4⁺ T cells. *Nat Immunol*. 2009 ;10:149-57.
108. Ziegler SF, Liu YJ. Thymic stromal lymphopoietin in normal and pathogenic T cell development and function. *Nat Immunol*. 2006 ;7:709-14.
109. Jiang Q, Li WQ, Aiello FB, Mazzucchelli R, Asefa B, Khaled AR, Durum SK. Cell biology of IL-7, a key lymphotrophin. *Cytokine Growth Factor Rev*. 2005 ;16:513-33.

110. Lin JX, Migone TS, Tsang M, Friedmann M, Weatherbee JA, Zhou L, Yamauchi A, Bloom ET, Mietz J, John S, et al. The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. *Immunity*. 1995 ;2:331-9.
111. Shiroki F, Matsuda S, Doi T, Fujiwara M, Mochizuki Y, Kadowaki T, Suzuki H, Koyasu S. The p85 α regulatory subunit of class IA phosphoinositide 3-kinase regulates beta-selection in thymocyte development. *J Immunol* 2007 ;178:1349–1356.
112. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. PI3K/Akt signaling pathway and cancer. *Cancer Treat Rev* 2004 ;30:193–204.
113. Gessner A, Vieth M, Will A, Schröppel K, Röllinghoff M. Interleukin-7 enhances antimicrobial activity against *Leishmania major* in murine macrophages. *Infect Immun*. 1993 ;61:4008-12.
114. Gessner A, Will A, Vieth M, Schröppel K, Röllinghoff M. Stimulation of B-cell lymphopoiesis by interleukin-7 leads to aggravation of murine leishmaniasis. *Immunology*. 1995 ;84:416-22.
115. Colpitts SL, Dalton NM, Scott P. IL-7 receptor expression provides the potential for long-term survival of both CD62L high central memory T cells and Th1 effector cells during *Leishmania major* infection. *J Immunol*. 2009 ;182:5702-11.
116. Pakpour N, Zaph C, Scott P. The central memory CD4⁺ T cell population generated during *Leishmania major* infection requires IL-12 to produce IFN-gamma. *J Immunol*. 2008 ;180:8299-305.
117. Kumari S, Singh S, Saha B, Paliwal PK. *Leishmania major* MAP kinase 10 is protective against experimental *L. major* infection. *Vaccine*. 2011 ;29:8783-7.

118. Gessner A, Vieth M, Will A, Schröppel K, Röllinghoff M. Interleukin-7 enhances antimicrobial activity against *Leishmania major* in murine macrophages. *Infect Immun.* 1993 ;61:4008-12.
119. Hoerauf A, Solbach W, Röllinghoff M, Gessner A. Effect of IL-7 treatment on *Leishmania major*-infected BALB.Xid mice: enhanced lymphopoiesis with sustained lack of B1 cells and clinical aggravation of disease. *Int Immunol.* 1995 ;7:1879-84.